EPS: As of FY2025 Q2, the actual value is USD -0.15.<h3>Segment Revenue</h3><ul><li>The company has not commenced any operations and does not expect to generate operating revenues until after the completion of an initial Business Combination.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: For the three months ended June 30, 2025, the company reported a net loss of $385,122, compared to a net income of $448,912 for the same period in 2024.</li><li>Formation and Operating Costs: For the three months ended June 30, 2025, formation and operating costs were $374,857, compared to $168,186 for the same period in 2024.</li><li>Interest Expense: For the three months ended June 30, 2025, interest expense was $28,345, compared to $23,059 for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: For the six months ended June 30, 2025, net cash used in operating activities was $183,512.</li><li>Net Cash Provided by Investing Activities: For the six months ended June 30, 2025, net cash provided by investing activities was $8,617,553, primarily due to cash withdrawn from the trust account in connection with redemption.</li><li>Net Cash Used in Financing Activities: For the six months ended June 30, 2025, net cash used in financing activities was $8,450,783, primarily due to cash paid for redemption of ordinary shares.</li></ul><h3>Unique Metrics</h3><ul><li>Trust Account: As of June 30, 2025, the company had $548,318 held in the Trust Account, which is intended to be used to complete the Business Combination.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company is focused on completing its initial business combination, with a proposed merger agreement with Semnur Pharmaceuticals, Inc. The total consideration to be paid at closing will be $2,500,000,000, payable in New Semnur Common Shares.</li><li>Non-Core Business: The company has entered into various agreements, including a Sponsor Interest Purchase Agreement and a Stockholder Agreement, to facilitate the business combination with Semnur Pharmaceuticals, Inc.</li><li>Priority: The company has extended its combination period through December 11, 2025, and is actively working towards completing the business combination with Semnur Pharmaceuticals, Inc.</li></ul>

DENALI CAPITAL ACQUISITION CORP UNIT 1 ORD A & 1 WT EXP (28/03/2027) | 10-Q: FY2025 Q2 EPS: USD -0.15